Immuneering Stock Rises 21.7% on Supply Agreement With LLY

Immuneering Corporation (IMRX) announced a clinical supply agreement with Eli Lilly (LLY) to evaluate its lead candidate, atebimetinib, in combination with Lilly’s olomorasib for KRAS G12C-mutant NSCLC in a planned Phase II study. This news drove IMRX shares up 21.7% yesterday, contributing to a 170.5% year-to-date increase. This marks Immuneering's second major collaboration this year, following a similar deal with Regeneron (REGN), with Immuneering retaining full worldwide development and commercialization rights for atebimetinib in both partnerships. The company's pipeline also shows promise for atebimetinib in pancreatic cancer, with early Phase IIa data indicating strong overall and progression-free survival rates, and a pivotal study anticipated in 2026.

Analysis

Immuneering Corporation (IMRX) has secured a significant clinical supply agreement with Eli Lilly (LLY), marking its second major pharmaceutical collaboration in 2025. The agreement facilitates a planned phase II study combining Immuneering's lead candidate, atebimetinib, with Lilly's olomorasib for KRAS G12C-mutant non-small cell lung cancer (NSCLC). This partnership, which follows a similar deal with Regeneron in February, significantly validates atebimetinib's potential by associating it with established industry players. Crucially, Immuneering retains full worldwide development and commercialization rights to its asset in both agreements, preserving maximum potential upside. The market reacted strongly, with IMRX shares gaining 21.7% on the news, contributing to a 170.5% year-to-date surge that vastly outperforms the industry's 4.1% rise. Beyond the collaborations, atebimetinib's pipeline progress in pancreatic cancer is also a key value driver, with initial phase IIa data showing a 94% overall survival and 72% progression-free survival at six months. With updated data expected in Q3 2025 and a pivotal study planned for 2026, the company is building a clear development pathway, although as a pre-revenue firm, its valuation remains entirely dependent on continued clinical success.

Key Decisions for Investors

• Investors should recognize the dual collaborations with Eli Lilly and Regeneron as significant de-risking events that validate the scientific premise of atebimetinib while Immuneering retains full commercial rights, a key value driver.
• Monitor the upcoming data release in Q3 2025 for the pancreatic cancer study, as this represents the next major catalyst that could impact the company's valuation.
• Given the stock's 170.5% year-to-date appreciation, new or existing investors should weigh the considerable pipeline potential against the valuation and the inherent binary risks associated with clinical-stage biotechnology firms.